OR WAIT null SECS
August 01, 2018
This article provides a sampling of the latest investments, expansions, and acquisitions by small-molecule contract service providers.
Why shouldn’t biopharmaceutical manufacturers be able to leverage standardized construction practices to improve time to market?
July 19, 2018
The agency has issued a warning letter for cGMP violations at a drug manufacturing facility in Ahmedabad, India, that Baxter gained through its acquisition of Claris Injectables.
July 18, 2018
Modern technologies, including Industry 4.0 and the Industrial Internet of Things, offer opportunities to increase biopharmaceutical manufacturing efficiency.
July 17, 2018
Moderna’s new manufacturing plant in Norwood, MA gives the company capacity for preclinical and Phase I and II clinical manufacturing for its mRNA development candidates, including personalized cancer vaccines.
July 10, 2018
The expansion at the company’s Gillingham, UK, site, worth EUR 9 million (approximately US$10.5 million), will improve the company’s distribution capabilities.
June 25, 2018
Minakem’s facility in Belgium enhances capacity to scale production of highly potent ingredients for small to full GMP batches.
June 22, 2018
The company has completed the first phase of expansion at its headquarters in Freiburg, Germany, in anticipation of increasing demand as cell and gene therapies approach commercialization.
June 21, 2018
The contract development and manufacturing company has received an additional approval from Health Canada to manufacture monoclonal antibody drug substance at its first plant in Icheon, South Korea.
June 07, 2018
The company will provide the first FlexFactory manufacturing platform for cell therapy manufacturing.